Oligonucleotide (Antisense oligonucleotide) · Gene silencing: UBE3A-ATS (UBE3A antisense transcript) · developed by Ultragenyx Pharmaceutical
Apazunersen (GTX-102) is an antisense oligonucleotide given as an oral spray and studied in Angelman syndrome and ataxia telangiectasia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06617429 | Phase 3 | Angelman Syndrome | Terminated | RARE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Angelman SyndromeAtaxia Telangiectasia
Updated Nov 15, 2026. Something wrong or missing? Report it on the RARE page.
See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RARE catalysts and pipeline →